Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 225

1.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L.

J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. Erratum in: J Clin Oncol. 2003 Jun 1;21(11):2226.

PMID:
12668651
[PubMed - indexed for MEDLINE]
2.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B.

Cancer Treat Rev. 2008 May;34(3):223-30. doi: 10.1016/j.ctrv.2007.11.004. Epub 2008 Jan 30.

PMID:
18234424
[PubMed - indexed for MEDLINE]
Free PMC Article
3.
4.

Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

Fumoleau P, Chauvin F, Namer M, Bugat R, Tubiana-Hulin M, Guastalla JP, Delozier T, Kerbrat P, Devaux Y, Bonneterre J, Filleul A, Clavel M.

J Clin Oncol. 2001 Feb 1;19(3):612-20.

PMID:
11157010
[PubMed - indexed for MEDLINE]
5.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M.

J Clin Oncol. 2010 Jun 10;28(17):2874-80. doi: 10.1200/JCO.2009.24.7643. Epub 2010 May 10.

PMID:
20458045
[PubMed - indexed for MEDLINE]
6.

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.

Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G.

Breast Cancer Res Treat. 2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4. Epub 2011 Dec 21.

PMID:
22187126
[PubMed - indexed for MEDLINE]
7.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C.

Clin Cancer Res. 2001 Dec;7(12):3934-41.

PMID:
11751485
[PubMed - indexed for MEDLINE]
Free Article
8.

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE.

J Clin Oncol. 2009 Jun 20;27(18):2938-45. doi: 10.1200/JCO.2008.20.3133. Epub 2009 Apr 13.

PMID:
19364964
[PubMed - indexed for MEDLINE]
9.

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N.

J Clin Oncol. 2005 Jun 1;23(16):3686-96. Epub 2005 May 16.

PMID:
15897552
[PubMed - indexed for MEDLINE]
10.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S.

J Clin Oncol. 2007 Feb 20;25(6):656-61.

PMID:
17308269
[PubMed - indexed for MEDLINE]
11.

Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G.

J Clin Oncol. 2007 Feb 1;25(4):405-10. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334.

PMID:
17264336
[PubMed - indexed for MEDLINE]
12.

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P.

J Natl Cancer Inst. 2005 Dec 7;97(23):1724-33.

PMID:
16333028
[PubMed - indexed for MEDLINE]
Free Article
13.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

International Breast Cancer Study Group, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A.

J Clin Oncol. 2006 Jan 20;24(3):370-8.

PMID:
16421418
[PubMed - indexed for MEDLINE]
14.

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N.

Cancer. 2002 Aug 15;95(4):681-95.

PMID:
12209710
[PubMed - indexed for MEDLINE]
Free Article
15.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ.

J Clin Oncol. 2002 Jul 15;20(14):3114-21.

PMID:
12118025
[PubMed - indexed for MEDLINE]
16.

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.

Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group.

J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83.

PMID:
15265969
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

PMID:
17430582
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.

Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE.

J Clin Oncol. 2010 Jan 1;28(1):77-82. doi: 10.1200/JCO.2009.22.1077. Epub 2009 Nov 9.

PMID:
19901117
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

PMID:
14679153
[PubMed - indexed for MEDLINE]
Free Article
20.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.

J Clin Oncol. 1999 Jan;17(1):93-100.

PMID:
10458222
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk